Vumerity was approved by the U.S. Food and Drug Administration (FDA) on October 30, 2019 [1].
What is Vumerity used for?
Vumerity, also known by its generic name diroximel fumarate, is prescribed for the treatment of relapsing forms of multiple sclerosis (MS) in adults [1]. This includes conditions such as clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS [1].
How does Vumerity work?
The precise mechanism by which Vumerity exerts its therapeutic effects in MS is not fully understood [1]. However, it is believed to involve its active metabolite, monomethyl fumarate (MMF), which may activate the Nrf2 pathway. This pathway is involved in cytoprotective genes and antioxidant responses, potentially helping to reduce inflammation and neurodegeneration associated with MS [1].
What are the potential side effects of Vumerity?
Common side effects reported with Vumerity include flushing, gastrointestinal issues such as nausea, vomiting, and diarrhea, as well as abdominal pain [1]. More serious potential side effects include liver enzyme elevations, a decrease in lymphocyte counts (lymphopenia), and progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection [1].
When does Vumerity's patent expire?
Information on Vumerity's specific patent expiry dates can be found on DrugPatentWatch.com [2]. Patent protection for drugs is complex and can involve multiple patents covering the drug itself, its formulation, and its methods of use.
Are there generic versions of Vumerity available?
As of its approval in 2019, Vumerity was a novel formulation. Generic versions of a drug typically become available after the expiration of key patents and any periods of market exclusivity. Information regarding generic availability can be tracked through resources like DrugPatentWatch.com [2].
How does Vumerity compare to other MS treatments?
Vumerity is a dimethyl fumarate (DMF) derivative, designed to be more tolerable regarding gastrointestinal side effects compared to the older DMF formulation [1]. It is part of a class of disease-modifying therapies (DMTs) for MS, which also includes injectables, infusions, and other oral medications. The choice of treatment depends on individual patient factors, disease activity, and physician recommendations.
What clinical data supports Vumerity's approval?
Vumerity's approval was based on clinical trial data, including the multi-center, randomized, double-blind, active-controlled study called EVOLVE-MS-1 [1]. This study evaluated the safety and efficacy of Vumerity in patients with relapsing forms of MS.
What patient concerns are associated with Vumerity?
Patients often have concerns about the efficacy of Vumerity in reducing relapses and slowing disease progression, as well as its safety profile. Managing potential side effects like flushing and gastrointestinal upset is a common focus for patients [1]. Awareness of serious risks like PML and liver function changes is also important.
Who manufactures Vumerity?
Vumerity is manufactured by Biogen [1].
Sources
1. FDA Approval Letter: Vumerity (diroximel fumarate) [1]
2. DrugPatentWatch.com [2]